Search

Your search keyword '"Catalano, Paul J."' showing total 745 results

Search Constraints

Start Over You searched for: Author "Catalano, Paul J." Remove constraint Author: "Catalano, Paul J."
745 results on '"Catalano, Paul J."'

Search Results

153. Disease-Free Survival Versus Overall Survival As a Primary End Point for Adjuvant Colon Cancer Studies: Individual Patient Data From 20,898 Patients on 18 Randomized Trials

161. Cisplatin, etoposide and either bleomycin or ifosfamide in the treatment of disseminated germ cell tumors: final analysis of an intergroup trial

164. Comprehensive genomic profiling of metastatic tumors in a phase II biomarker study of everolimus in advanced renal cell carcinoma

169. Association of human endogenous retrovirus (hERV) expression with clinical efficacy of PD-1 blockade in metastatic clear cell renal cell carcinoma (mccRCC).

171. irRECIST for the Evaluation of Candidate Biomarkers of Response to Nivolumab in Metastatic Clear Cell Renal Cell Carcinoma: Analysis of a Phase II Prospective Clinical Trial

172. Neurosurgical Resection and Stereotactic Radiation Versus Stereotactic Radiation Alone in Patients with a Single or Solitary Brain Metastasis

173. Genetic variation in DNA-repair pathways and response to radiochemotherapy in esophageal adenocarcinoma: a retrospective cohort study of the Eastern Cooperative Oncology Group

176. GSTM1 and APE1 genotypes affect arsenic-induced oxidative stress: a repeated measures study

178. Master Protocol Trial Design for Efficient and Rational Evaluation of Novel Therapeutic Oncology Devices.

181. Randomized trial of irinotecan and cetuximab (IC) versus irinotecan, cetuximab and ramucirumab (ICR) as 2nd line therapy of advanced colorectal cancer (CRC) following oxaliplatin and bevacizumb based therapy: Result of E7208

182. A randomized study of temozolomide or temozolomide and capecitabine in patients with advanced pancreatic neuroendocrine tumors: A trial of the ECOG-ACRIN Cancer Research Group (E2211).

183. Evaluation of predictive biomarkers for nivolumab in metastatic clear cell renal cell carcinoma (mccRCC) using RECIST and immune-related (IR) RECIST.

184. Cabozantinib in Patients with Advanced Merkel Cell Carcinoma

185. Phase 2 study of treatment selection based on tumor thymidylate synthase expression in previously untreated patients with metastatic colorectal cancer: A trial of the ECOG-ACRIN Cancer Research Group (E4203)

186. Brain Metastases in Newly Diagnosed Breast Cancer

188. Incidence and prognosis of patients with brain metastases at diagnosis of systemic malignancy: a population-based study

189. The association of tumor infiltrating CD8+ and Foxp3+ cells with overall response rate (ORR) in metastatic renal cell carcinoma (mRCC) patients treated with high-dose aldesleukin (HD IL-2).

190. PrE0204: A multi-institutional, single arm, two-stage phase II trial of nab-paclitaxel and gemcitabine for first-line treatment of patients with advanced or metastatic cholangiocarcinoma—A PrECOG LLC study.

191. Prognostic importance of p16 status for women with vulvar squamous cell carcinoma (SCC) treated with radiotherapy.

194. Impact of immune checkpoint protein expression in tumor cells and tumor infiltrating CD8+ T cells on clinical benefit from PD-1 blockade in metastatic clear cell renal cell carcinoma (mccRCC).

196. ARDS in the setting of FOLFOX/cetuximab based chemoradiotherapy for locally advanced esophageal adenocarcinoma (E2205).

197. Doxorubicin and subsequent risk of cardiovascular diseases among survivors of diffuse large B-cell lymphoma in Hong Kong

198. Effects of Postmastectomy Radiation Therapy on Immediate Tissue Expander and Acellular Dermal Matrix Reconstruction: Results of a Prospective Clinical Trial.

199. Advanced pancreatic cancer clinical trials: The continued underrepresentation of older patients.

200. Breast cancer subtype and intracranial recurrence patterns after brain-directed radiation for brain metastases.

Catalog

Books, media, physical & digital resources